The role of open innovation in biomarker discovery

Lilla Landeck, Monika Lessl, Andreas Busch, Matthias Gottwald, Khusru Asadullah

Abstract

Precision medicine aims to treat diseases with special consideration for the individual biological variability. Novel biomarkers (BM) are needed to predict therapeutic responses and to allow for the selection of suitable patients for treatment with certain drugs. However, the identification and validation of appropriate BMs is challenging. Close col-laboration between different partners seems to be a key success factor. While the importance of partnerships and larger, well-established consortia in BM discovery such as the pharmaceutical industry and academic institutions is well un-derstood and has been investigated in the past, the use of open-innovation models, also known as ‘crowd sourcing for biomarkers’, is still in its infancy. Crowd sourcing comprises of a —usually via internet— request for problem solution to an open group of users in a kind of an ‘open call’. The community (crowd) is asked to provide solutions. Since the application of the crowd sourcing method offers the possibility to collect as many as possible novel ideas from a broad community with different expertise, this approach is particularly promising for BM development. In this article we de-scribe the first examples of open-innovation models, such as the ‘grants for targets’ (G4T) and biomarkers initiative ‘InnoCentive’ (innovation/incentive) platform. They may be a fruitful basis for collaborative BM development in the future.

Full Text:

PDF

References

Landeck L, Kneip C, Reischl J, et al. 2016, Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology. Experi-mental Dermatology, vol.25(5): 333–339.

Scannell J W, Blanckley A, Boldon H, et al. 2012, Diag-nosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, vol.11: 191–200.

Arrowsmith J, 2011, Phase II failures: 2008–2010. Nature Reviews Drug Discovery, vol.10: 328–329.

Salter H and Holland R, 2014, Biomarkers: refining

diagnosis and expediting drug development — reality, aspiration and the role of open innovation. Journal of In-ternal Medicine, vol.276: 215–228.

Lessl M, Bryans J S, Richards D, et al. 2011, Crowd sourcing in drug discovery. Nature Reviews Drug Dis-covery, vol.10: 241–242.

Landeck L, Lessl M, Reischl J, et al. 2016, Collaboration for success: the value of strategic collaborations for pre-cision medicine and biomarker discovery. Advances in Precision Medicine, vol.1(1): 25–33.

Asadullah K, Busch A, Gottwald G, et al. 2015, Indus-trial–academic collaborations for biomarkers. Nature Re-views Drug Discovery, vol.14: 805–806.

Wholley D, 2014, The biomarkers consortium. Nature Reviews Drug Discovery, vol.13(11): 791–792.

Stephenson D and Sauer J M, 2014, The predictive safety testing consortium and the coalition against major disea-ses. Nature Reviews Drug Discovery, vol.13(11): 793–794.

Lessl M and Douglas F, 2010, From technology-transfer to know-how interchange. Wissenschaftsmanagement, vol.2: 34–41.

Howe J, 2008, Crowdsourcing: Why the Power of the Crowd is Driving the Future Business. New York: Crown Publishing Group.

Lessl M, Schoepe S, Sommer A, et al. 2011, Grants4-targets — an innovative approach to translate ideas from basic research into novel drugs. Drug Discovery Today, vol.16(7–8): 288–292.

Dorsch H, Jurock AE, Schoepe S, et al. 2015, Grants4-Targets: an open innovation initiative to foster drug dis-covery collaborations between academia and the phar-maceutical industry. Nature Reviews Drug Discovery, vol.14: 74–76.

Chesbrough H, 2003, Open Innovation: The New Impera-tive for Creating and Profiting from Technology. Cam-bridge, MA: Harvard Business School Publishing.

Gassmann, O, Enkel E, Chesbrough H, 2010, The future of open innovation. R&D Management, vol.40(3): 213– 221.


DOI: http://dx.doi.org/10.18063/APM.2016.02.007.
(386 Abstract Views, 245 PDF Downloads)

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Lilla Landeck, Monika Lessl, Andreas Busch, Matthias Gottwald, Khusru Asadullah

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

 

                                          

Advances in Precision Medicine is a peer-reviewed, open-access journal. All journal content, except where otherwise noted, is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.